T he epidermal growth factor receptor (EGFR, c-ErbB-1, HER-1) is a member of the HER family of receptors, which includes HER-2, a receptor targeted in breast cancer therapy (Baselga, 2002) . The EGFR is expressed in many human tumors, including colorectal (Messa, Russo, Caruso, & Di Leo, 1998; Salomon, Brandt, Ciardiello, & Normanno, 1995) , bladder, brain, cervical, esophageal (Salomon et al.) , head and neck (Rubin Grandis, Melheim, Barnes, & Tweardy, 1996) , renal cell (Salomon et al.) , lung (Rusch et al., 1997) , ovarian (Bartlett et al., 1996) , pancreatic (Yamanaka et al., 1993) , prostate (Salomon et al.) , and breast cancers (Bucci et al., 1997; Klijn, Berns, Schmitz, & Foekens, 1992) . The activation of the EGFR by its natural ligands, such as epidermal growth factor or transforming growth factor-a, can lead to increased cell proliferation, inhibition of programmed cell death (apoptosis), promotion of angiogenesis, and stimulation of metastasis (Baselga, 2000 (Baselga, , 2002 Woodburn, 1999) (see glossary on page 338).
Cetuximab is a chimeric immunoglobulin G1 monoclonal antibody (Mendelsohn, 2000) . It is one of several targeted biologic agents that have been developed to selectively inhibit or reverse tumorigenic processes, with relative sparing of normal proliferating cells. Cetuximab has been designed to bind to the extracellular domain of the EGFR, blocking its natural ligands and the oncogenic processes associated with its activation (Mendelsohn) . esophageal, pancreatic, kidney, ovarian, and breast cancers, with a generally favorable toxicity profi le; the maximum tolerated dose has not been defi ned (Bos et al., 1996; Falcey et al., 1997) . Partial responses and stable disease were reported in more than one-third of the patients with irinotecan-refractory colorectal cancer included in a recently reported trial (Saltz et al., 2004) . In a randomized, phase II trial of irinotecan-refractory, metastatic colorectal cancer, patients treated with single-agent cetuximab achieved partial responses in 10.8% of cases, and the disease control rate was 32.4%; patients receiving cetuximab plus irinotecan exhibited partial response and overall disease control rates of 22.9% and 55.5%, respectively; and median times to tumor progression in each arm were 1.5 This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org. and 4.1 months, respectively (Cunningham et al., 2003) . Comparison of the singleagent and combination regimens indicated that the partial response rate, overall disease control rate (partial response and stable disease), and median time to progression were signifi cantly greater in patients treated with cetuximab and irinotecan (Cunningham et al.) .
Because of the growing interest in these agents in general and cetuximab specifically, oncology nurses will need to manage the toxicities observed in patients receiving them (Wood, 2002) . This article outlines the clinically relevant adverse events associated with cetuximab. Recommendations for the prevention and treatment of the adverse events are presented. Additionally, a number of issues should be addressed with patients prior to beginning treatment with cetuximab (see Figure 1 ).
Adverse Events Associated With Cetuximab
Cetuximab can be administered safely in appropriate outpatient settings. Most of the adverse events observed in patients treated with targeted biologic agents such as cetuximab are very different from and generally of less concern than those typically seen in patients treated with traditional chemotherapy regimens (Riddle, Lee, & Purdom, 2002; Waxman & Herbst, 2002) . In comparison with the serious toxic effects of chemotherapy, which are well known and may include myelosuppression, febrile neutropenia, and nausea and vomiting, the overall safety profi le of cetuximab is favorable.
Several studies have been conducted to evaluate the use of cetuximab in patients with EGFR-expressing metastatic colorectal cancer that had progressed after irinotecanbased therapy. The safety profi le of singleagent cetuximab (n = 279) and cetuximab plus irinotecan (n = 354) was defi ned (see Table 1 ). The most frequent adverse events in patients treated with single-agent cetuximab or cetuximab plus irinotecan are presented in Table 2 . Cetuximab did not appear to increase the frequency or severity of irinotecan-associated toxicities. The three most clinically relevant adverse events with cetuximab are severe infusion reactions, acneform skin rash, and nail disorder.
• Severe (grade 3 or 4) infusion reactions are uncommon (3% incidence in patients treated with cetuximab plus irinotecan and 2% in patients treated with singleagent cetuximab) but can be life threatening. Thus, vigilant monitoring of patients during infusion is important.
• Grade 1 or 2 acneform skin rash can affect quality of life; severe cases (grade 3 or 4), which are rare, generally require dose interruption and reduction but resolve without scarring after treatment.
• The nail disorder associated with cetuximab treatment can be painful but rarely is severe. The incidence of nail disorder of any grade and grade 3 or 4 in patients treated with cetuximab plus irinotecan was 12% and < 1%, respectively, and 16% and < 1%, respectively, in patients treated with single-agent cetuximab.
The following discussion provides an overview of the clinically relevant adverse events with cetuximab, as well as recommendations for appropriate care to control and treat them.
Infusion Reactions Reactions Usually Are Mild
Infusion reactions result from immunologic responses that can occur with the administration of any therapeutic agent. Infusion reactions also are a main class-specifi c side effect associated with monoclonal antibody therapy. Although mild to moderate infusion reactions are not uncommon, severe reactions occur infrequently. In the four trials defi ning the toxicity profi le of cetuximab, severe (grade 3 or 4) infusion reactions were observed in 3% of patients treated with cetuximab plus irinotecan. This proportion ___ An infusion reaction to cetuximab is possible during administration, although it is rarely severe, and it may include fever, chills, headache, stiffness, or respiratory distress. The appearance of symptoms will be monitored continually, and medical assistance will be provided if needed. ___ Medicine is given prior to cetuximab infusion to minimize the likelihood of an infusion reaction. ___ Acneform skin rash is a relatively common side effect that typically appears on the face, upper chest, and back but also occasionally extends to the extremities. It usually is observed within two weeks of the beginning of therapy. The symptoms may include dry skin and infl amed areas of the skin that may contain pus. ___ To prevent or lessen the severity of an acneform skin rash, prevent skin irritation by avoiding exposure to sunlight, harsh winds, and harsh detergents or perfumes and refraining from wearing tight-fi tting clothing. ___ The doctor or nurse should be informed of the occurrence of skin rash. Treatments that can aid in healing include antibiotic creams such as topical clindamycin. ___ The rash is not a sign of an allergic reaction. ___ The absence of an acneform skin rash does not mean that cetuximab is not working because some patients who did not experience a rash experienced reduction in tumor size. ___ The presence of an acneform skin rash does not guarantee that cetuximab is working. ___ The acneform skin rash gradually disappears without scarring after treatment with cetuximab ceases. ___ Small wounds can form on the skin along the edges of fi ngernails and toenails during cetuximab therapy, although they are observed infrequently. Antibiotic treatments can aid in healing. ___ Diarrhea frequently accompanies treatment with irinotecan and is the most common severe adverse event that patients treated with cetuximab plus irinotecan experience. Diarrhea can be severe and requires treatment. is consistent with the rate reported for other monoclonal antibody therapies and other classes of agents that can cause severe infusion reactions, such as the taxanes. Most infusion reactions are short lived and consist of symptoms that often are fl ulike, with fever, chills, headaches, rigors, and respiratory distress among the common side effects.Severe, potentially fatal allergic or infusion reactions, characterized by rapid onset of airway obstruction (bronchospasm, stridor, and hoarseness), urticaria, and hypotension, when they occur, typically are observed with the fi rst dose of cetuximab. The National Cancer Institute common toxicity criteria for allergic or infusion reactions are provided in Table 3 .
Control and Treatment
The fi rst administration of cetuximab is the most common time when a severe allergic or infusion reaction is observed (Riddle et al., 2002) . However, vigilance in patient monitoring by physicians and nurses throughout the entire treatment period is important because of the need to respond immediately to patients exhibiting symptoms of infusion reactions of any grade (Zanotti & Markman, 2001 ). Individual treatment centers should have their own protocols in place for the treatment of infusion reactions associated with chemotherapy and monoclonal antibody therapy. These plans typically include appropriate medical supervision and resources for the treatment of infusion reactions, including reliable IV access (Zanotti & Markman) . Figure 2 reviews procedures that should be used to manage anaphylactic reactions such as those that can accompany cetuximab infusion. The following steps should be taken to protect patients during every infusion of cetuximab.
• Baseline vital sign measurements, including body temperature, blood pressure, heart rate, and respiration rate, should be obtained for all patients. The baseline measurements are required for comparison in diagnosing fever and hypotension, which are among the symptoms of infusion reactions.
• Premedication with an H 1 blocker (e.g., 50 mg IV diphenhydramine hydrochloride) is required to minimize the chances of infusion reactions. • A low protein binding 0.22-micron inline fi lter should be used for IV infusion of cetuximab. Although most infusion reactions occur during the fi rst exposure to cetuximab, some patients experience their fi rst infusion reactions later in their administration schedules. Therefore, caution should be exercised with every infusion. Figure 3 provides a fl owchart for the control and treatment of infusion reactions.
Although no specifi c recommendations exist, monitoring of vital signs should occur midway through cetuximab infusion, at the completion of infusion, and one hour after infusion is completed. In all cases in which infusion reaction symptoms of any grade are observed, the infusion of cetuximab should be stopped to ensure that a reaction does not worsen. Vital sign measurements should be performed as soon as possible after a patient exhibits any infusion reaction-related symptom. If a severe infusion reaction (grade 3 or 4) is observed, the infusion of cetuximab should be discontinued immediately and should not be attempted again. Appropriate medical therapy should be administered, which may include fl uids, epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen. Patients exhibiting severe infusion reactions should be monitored closely until all signs and symptoms resolve. In the case of mild None Transient rash and drug fever < 38°C (< 100.4°F) Urticaria, drug fever > 38°C (> 100.4°F), and asymptomatic bronchospasm Symptomatic bronchospasm requiring parenteral medication(s) with or without urticaria and allergy-related edema and angioedema Anaphylaxis Transient fl ushing or rash and drug fever < 38°C Rash, fl ushing, urticaria, dyspnea, and drug fever > 38°C (> 100.4°F) Symptomatic bronchospasm with or without urticaria, parenteral medication(s) indicated; allergy-related edema and angioedema and hypotension Anaphylaxis Death
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to moderate infusion reactions (grade 1 or 2), the infusion of cetuximab may proceed at a reduced infusion rate, often half of the initial rate, which should be used for all subsequent treatments.
Acneform Skin Rash Most Common Adverse Event
The most common adverse event reported after treatment with cetuximab is an acneform skin rash that typically appears on the face, upper chest, and back but also occasionally extends to the extremities (Riddle et al., 2002) . The rash is characterized by multiple pustular-or follicular-appearing lesions. Some patients suffering from rash also have complained about dry skin. The acneform skin rash is not dose limiting, usually is observed within two weeks of the beginning of therapy, and generally resolves without scarring after discontinuation of treatment (Hollywood, 2002) .
Results from the four trials assessing the toxicity profi le of cetuximab showed that acneform skin rash incidence of any grade was 88% and 90% in patients receiving cetuximab plus irinotecan and single-agent cetuximab, respectively. The incidences of grade 3 acneform skin rash were 14% and 10%, respectively.
At the author's institution, the most frequent complaints of patients with acneform skin rash relate to changes in appearance. Patients have not complained about the rash being itchy or painful, although some have reported particular irritation when the rash appeared in certain places, such as a nostril. Patients should understand, however, that a rash is likely and be informed of its appearance and frequency. Patients also should understand that a rash is not a sign of allergic reaction so that they will not mistake it for an infusion reaction.
The presence and grade of acneform skin rash were signifi cantly correlated with patient survival in three of four studies that were analyzed retrospectively. Saltz, If hypersensitivity or anaphylaxis is suspected, • Immediately discontinue chemotherapy infusion and maintain an infusion of normal saline solution.
• Notify the attending physician of signs and symptoms of hypersensitivity reaction or anaphylaxis.
• Assess the patient for respiratory or cardiac compromise. Notify the emergency code team if necessary and available. Contact fi rst-response team per local protocols.
• Initiate the emergency protocol; have the emergency or code cart nearby.
• Set up oxygen, ambu bag, and suction machine to maintain the airway. Have suction catheters ready.
• Monitor and assess the patient every 2 minutes until stable, then every 5 minutes for 30 minutes, then every 15 minutes, documenting vital signs and physical symptoms.
• Locate recent weight on fl ow sheet; this may be used later to dose medications.
To maintain the airway,
• Use head tilt with chin lift to maintain airway.
• Prepare for intubation, with intubation tray and oxygen nearby.
• Have tracheostomy tray available.
• To maintain respirations with -Hypersensitivity reaction: Administer epinephrine-the single most important step.
-Urticaria, angioedema: Administer 0.5 mg epinephrine (1:1,000 solution = 0.5 ml subcutaneously every 15 minutes). -Mild bronchospasm: Administer oxygen 10 L per minute via face mask or 2 L per minute by nasal cannula for chronic obstructive pulmonary disease. -Severe bronchospasm or respiratory or cardiac arrest: Administer epinephrine 1 mg via IV over fi ve minutes (1:1,000 in 10 ml prefi lled syringe). Repeat every fi ve minutes as needed for up to three doses. Additional doses may be ordered by a physician. Attach oxygen resuscitation bag and provide artifi cial respiration, if required.
To maintain circulation,
• Give normal saline solution at a rapid rate.
• Place patient in the Trendelenburg position (feet elevated) unless he or she is in respiratory distress.
• Ready the following medications, but do not administer them until they are prescribed by the emergency team.
-Aminophylline: Loading dose is 6 mg/kg over 20-30 minutes (not useful in acute bronchospasm). Maintenance dose is every four to six hours. -Albuterol aerosolized: 2 inhalations repeated every four to six hours -Diphenhydramine: 50 mg IV push administered over fi ve minutes -Hydrocortisone: 100-200 mg IV push over at least 30 seconds -Methylprednisolone sodium succinate: 60-125 mg IV push over at least 30 seconds -Dopamine: 2-20 mcg/kg per minute via IV to maintain blood pressure and organ perfusion -Atropine: 0.4-1 mg every one to two hours; larger doses up to a maximum of 2 mg may be required.
FIGURE 2. GENERAL PROTOCOL FOR THE MANAGEMENT OF INFUSION REACTIONS
Note. Based on information from Ream & Tunison, 1998; RxMed, 2005 .
• Continue with infusion at a reduced rate.
FIGURE 3. RECOMMENDATIONS FOR THE CONTROL AND TREATMENT OF INFUSION REACTIONS ASSOCIATED WITH CETUXIMAB TREATMENT
Note. Based on information from ImClone Systems Incorporated, 2004; Zanotti & Markman, 2001 .
Control

Monitoring
Treatment
• Measure baseline vital signs.
• Premedicate with antihistamines.
Cetuximab administration using a low protein binding 0.22-micron in-line fi lter
• Monitor for infusion reaction symptoms.
• Measure vital signs periodically.
Infusion reaction
No infusion symptoms reaction symptoms
• Discontinue infusion.
• Measure vital signs.
• Continue to monitor for infusion reaction symptoms.
Severe
Mild to moderate (grade 3 or 4) (grade 1 or 2) infusion reaction infusion reaction
• Administer appropriate medical therapy.
• Closely monitor until symptoms resolve. • Do not attempt later administration.
Kies, Abbruzzese, Azarnia, and Needle (2003) suggested that a rash may predict a positive clinical outcome for a patient. Any patient who does not exhibit signs of rash must be kept on therapy, because responses have been observed in patients who did not experience a rash. Alternatively, the presence of a rash does not guarantee clinical improvement. The relationship between a prior history of acne and increased likelihood or severity of acneform rash has yet to be determined defi nitively.
Control and Treatment
Basic steps should be taken to help prevent the onset or an increase in severity of acneform skin rash. Patients should stay away from skin irritants, including exposure to sunlight, harsh winds, and harsh detergents or perfumes and should avoid wearing tight-fi tting clothing.
For the fi rst occurrence of severe (grade 3 or 4) acneform skin rash (see Table 4 ), treatment with cetuximab should be interrupted. Treatment may resume at the same dose if the rash resolves to grade 2 or less. If a grade 3 or 4 acneform skin rash recurs, treatment with cetuximab should be delayed again, and subsequent administration should proceed with reductions of the cetuximab dose to 200 mg/m 2 , then 150 mg/m 2 . With these guidelines in place, the author's treatment center has not yet had to reduce the dose of cetuximab administered to any patients for acneform skin rash.
General recommendations for the treatment of acneform skin rash symptoms include the use of antibiotic creams, including topical clindamycin. The use of topical corticosteroids generally is not recommended for the treatment of acneform rash. Figure 4 provides a fl owchart for the control and treatment of acneform skin rash.
Nail Disorder
Although they have not been observed at the author's institution, nail disorders associated with cetuximab treatment have been reported and sometimes are painful. The reported incidence rates of nail disorder are 12% in patients treated with cetuximab plus irinotecan and 16% in patients treated with single-agent cetuximab. Nail disorder has been observed most commonly on the great toes and thumbs and is characterized by paronychial infl ammation of the lateral nail folds. Figure 5 shows a photograph of the great toe of a patient with nail disorder.
The pain associated with nail disorder has been described as low in intensity and "annoying" but capable of throbbing when struck. The National Cancer Institute common toxicity criteria for nail changes are provided in Table 5 .
Control and Treatment
The typical treatments that are used to treat nail disorder include systemic and topical antibiotics. Aggressive pain relief medications typically are not required to alleviate the pain associated with nail disorder.
Additional Safety Issues
In addition to the adverse events described earlier, other uncommon but potentially severe adverse events have been observed in patients treated with cetuximab. They include fever (5%), sepsis (3%), kidney failure (2%), pulmonary embolus (1%), dehydration (5%, cetuximab plus irinotecan; 2%, single-agent cetuximab), and diarrhea (6%, cetuximab plus irinotecan; 0%, single-agent cetuximab). Additionally, interstitial lung disease (ILD) has been reported in 3 of 633 (0.5%) patients treated with cetuximab, including one fatal case of noncardiogenic pulmonary In the author's experience, the addition of cetuximab to a regimen including chemotherapeutic agents does not require extra precautions beyond those required for chemotherapy, and no comorbid conditions in patients raise special concerns.
The effect of cetuximab on reproductive capability or fetal health when administered during pregnancy is not known. Therefore, cetuximab should be used in pregnant women only when the potential benefi t outweighs the potential risk to the fetus. Women should be alerted to the potential risk for loss of pregnancy or hazard to the fetus if cetuximab is used during pregnancy or if a woman becomes pregnant while receiving cetuximab. Cetuximab should not be mixed or diluted with other drugs because no studies have examined the compatibility of cetuximab with other agents. 
